๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
AptarGroup, Inc. (ATR)
NYSE: ATR ยท Real-Time Price ยท USD
140.08
-0.26 (-0.19%)
Nov 20, 2026, 4:00 PM EST - Market closed

AptarGroup Earnings Call Transcripts

Fiscal Year 2026

Fiscal Year 2025

  • Q4 and full-year 2025 saw strong sales growth and robust innovation, with all segments delivering core sales gains. Margins were pressured by mix and operational issues, but sequential improvement is expected in 2026. Emergency medicine remains a headwind, but pharma, beauty, and closures show positive momentum.

  • Pharma drives growth and profitability, with proprietary drug delivery systems and a robust pipeline in chronic and emerging therapies. Injectables and nasal delivery are key growth areas, supported by steady CapEx, targeted M&A, and increased share repurchases amid strong shareholder returns.

  • Q3 saw adjusted EPS of $1.62, with pharma growth in injectables and drug delivery, offset by consumer healthcare destocking. Emergency medicine faces a 35% revenue decline in 2026, compressing margins, but long-term pharma growth targets remain intact.

  • Investor Day 2025

    Raised ROIC and dividend targets reflect strong execution, with all segments contributing to profitable growth. Pharma leads with innovation and a robust pipeline, while Beauty and Closures drive efficiency and regional expansion. Sustained cost management, automation, and disciplined capital allocation underpin long-term targets.

  • Q2 results exceeded guidance with 18% EPS growth and strong performance across all segments, led by Pharma and Closures. Outlook for Q3 is cautious due to naloxone normalization, legal expenses, and ongoing European inventory headwinds, but innovation and capital returns remain robust.

  • Pharma is the primary growth engine, supported by proprietary technology, global operations, and a strong sustainability focus. Financial targets were raised in 2023, with robust pipeline diversification and disciplined capital allocation. Digital health and innovative packaging drive additional growth.

  • The event highlighted robust long-term growth targets, a strong balance sheet, and disciplined capital allocation, with pharma as the main growth driver. Beauty and closures segments are positioned for recovery, while a resilient supply chain mitigates tariff and geopolitical risks.

  • Adjusted EPS rose 5% year-over-year (currency and tax neutral), with pharma and active materials driving growth despite flat core sales and a 3% FX headwind. Beauty and closures showed sequential improvement, and Q2 guidance anticipates stronger EPS and limited tariff impact.

  • Pharma is the largest and fastest-growing segment, driving value through proprietary technology, global reach, and sustainability leadership. Growth is fueled by innovation in nasal and injectable drug delivery, robust pipeline management, and digital health expansion. Financial targets have been raised, with strong capital allocation and a focus on operational excellence.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018